SITC Archive Library

SITC 30th Anniversary Annual Meeting (2015): Cutting-Edge Clinical Trials
November 6-8, 2015
Gaylord National Hotel & Convention Center National Harbor, MD

Session Co-Chairs 
Sandra Demaria, MD – New York University School of Medicine
Elizabeth M. Jaffee, MD – Johns Hopkins University

SITC 30th Anniversary Annual Meeting Organizers
Sandra Demaria, MD – Weill Cornell Medical College
Madhav Dhodapkar, MD – Yale University
Pamela S. Ohashi, PhD – Princess Margaret Cancer Centre
Jennifer A. Wargo, MD – University of Texas MD Anderson Cancer Center
Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute

Program Summary
Antibodies targeting immune checkpoint receptors on T cells and their ligands in the tumor microenvironment have shown unprecedented ability to cause durable tumor regression in advanced metastatic cancers refractory to other treatments. Importantly, for a long time, only tumors considered relatively immunogenic such as melanoma and renal cell carcinoma were considered good candidates for immunotherapy. We are now learning that the immunologic phenotype of a tumor, as reflected by the nature and extent of the immune infiltrate, may be more important than its histogenesis in predicting response to immunotherapy. We have also learned that conventional cytotoxic treatments can promote anti-tumor immune responses and potentially synergize with immunotherapy. This session at the SITC 30th Anniversary Annual Meeting on Friday, November 6, 2015 in National Harbor, MD provided examples of cutting edge clinical trials informed by this new knowledge and testing the benefits of immunotherapy in novel combinations and in new tumor types. Immune biology-driven early clinical trials are showing promising results auspicious of a truly revolutionary change in cancer treatment.

About the SITC 30th Anniversary Annual Meeting:
SITC's 30th Anniversary Annual Meeting provided a multidisciplinary educational and interactive environment focused on improving the outcome for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy research. The meeting consisted of cutting-edge research presentations by experts in the field, oral and poster abstract presentations and ample opportunity for both structured and informal discussions including important networking opportunities. In addition, the meeting included updates on major national and international initiatives coming from academia, government and industry, as well as ongoing SITC projects.

Target Audience
The target audience for this program included basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, researchers, graduate students, post-doctoral fellows, and allied health professionals involved in cancer research as well as pharmacists and payers that wished to learn more about cancer immunology and immunotherapy and its incorporation into current (and future) effective cancer treatment.


#2015 #AnnualMeeting #ClinicalTrials 
#BrainCancers #HeadandNeckCancers #PresentationSlides #SITC #CombinationTherapy
#Ipilimumab #Vaccines #AdoptiveCellTherapy #Clinician #Industry #Oncologist #Researcher #Video